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CGRAY et al. (1953) suggested that the
oxygen concentration in tumour cells
might influence the curability of some
human cancers by ionizing radiation.
Recent clinical investigations using hyp-
oxic cell radiosensitizers (Urtasun et al.,
1976), hyperbaric oxygen (Henk & Smith,
1977) and pretherapy transfusion of
anaemic patients (Bush et al., 1978) con-
firnm the postulate that lhypoxia does in-
fluence the radiocurability of some
tumours. Although the oxygenation status
of tumours is considered to be important
information for clinical oncologists, no
technique is currently available to provide
such information for individual tumours.
The techniques developed for measuring
the fraction of hypoxic cells in animal
tumours, and their reoxygenation during
a course ofradiotherapy, are not ofroutine
clinical use because they are invasive and/
or destructive (Chapman et al., 1981).
A property of hypoxic cell radiosensi-
tizers (Adams, 1973), which might be
exploited for the detection of hypoxia
within solid tumours, is that nitroaromatic
drugs become covalently bound to the
macromolecules of hypoxic cells by
metabolism-induced (McCalla et al., 1970)
and radiation-induced (Chapman et al.,
1972) processes. Mechanisms ofbinding by
both processes are currently being in-
vestigated in mammalian cell cultures,
multicellular spheroids and animal
tumours. Studies with Chinese hamster
V79 cells in suspension culture (to be
reported in detail elsewhere) indicated
that the amount of 14C-misonidazole
(MISO) bound to hypoxic cells after 2h
incubation at 37°C was equal to that
bound by several kilorads of radiation.
Subsequent efforts were directed towards
exploiting this metabolism-induced pro-
cess for labelling hypoxic cells in multi-
cellular systems. The level of 14C-MISO
bound to hypoxic cells after 2h incubation
cain lead to several disintegrations of 14C
per cell in 14 days, an activity which
should be readily detected by auto-
radiography.
Multicellular spheroids of Chinese ham-
ster V79 cells were incubated for 3 h at
370C with 50,UM 14C-MISO (sp. act. 144
,uCi/mg, generously supplied by Hoffman
La Roche, Nutley, N.J.). The spheroids
were removed from the labelled medium
by sedimentation, washed with unlabelled
saline, fixed in 10% buffered formalin,
embedded and sectioned at 4 ,m. Sections
mounted on microscope slides were dipped
in liquid emulsion (Kodak NTB3) and
exposed for various lengths of time. After
development of the emulsion the sections
were stained with haematoxylin.
Fig. 1 shows an autoradiograph (ARC,
exposed for 17 days) of a section from
some smaller spheroids (-% 0-15 mm in
diameter) which would not be expected to
contain hypoxic cells. Very few grains can
be detected in the emulsion over this
section, indicating that the procedures for
washing unbound 14C-MISO from the
specimen were efficient. Fig. 2 shows an
ARG (exposed for 17 days) of a sectionMARKER FOR HYPOXIC CELLS54
Fie,. I.-An ARG (exposed for 17 days, as in otherfigures) of a section ofsmallspheroids 0-15 mm
in diameter) which had been exposed to 50,um 14C-MISO for 3 h at 37'C.
....
w
j
Vit. pa, F. X
.2
FIG. 2.-ARG of a section of spheroid (,0-6 mm in diameter) which had been exposed to 50jum
14C-MISO for 3 h at 370C.
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FIG. 3.-ARG of a section of an EMT-6 tumour (-P5 x 0-5 mm) which had been exposed in vivo to
, 50gM 14C-MISO for 3 h.
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FIc. 4.-ARG of a section of an EMT-6 tumour ( -0 x 2-0 mm) which had been exposed in vivo to
,-50jM 14C-MISO for 3 h.
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from a 0-6mm diameter spheroid which
has pyknotic cells and necrosis at its
centre. In contrast to the spheroids in
Fig. 1, there is evidence for retained 14C.
MISO in the cells immediately surrounding
the pyknotic and necrotic region. This
pattern of binding of radiosensitizer to
cells 15-20 cell layers deep was consistent
between serial sections of the same
spheroid and between different spheroids
of similar size. The radioactively labelled
sensitizer appears to be selectively bound
to the metabolizing hypoxic cells in the
spheroid and, indeed, might be marking
for the first time at a histological level
those cells which are resistant to radiation.
Of course, much additional work is re-
quired to confirm such a conclusion.
EMT-6 fibrosarcomas of various sizes
were grown at different s.c. sites in the
same BALB/c mouse from inocula of
different cell numbers. When the largest
tumour was found on palpation to be
0 5 cm in diameter, the animal was
injected i.p. with 14C-MISO (sp. act. 144
uCi/mg) to achieve a maximum serum
concentration of 50 um. Additional
radioactive drug was administered at 1
and 2 h to simulate an exposure of the
hypoxic tumour cells to a constant con-
centration. Three h after the initial dose
of drug the animal was killed and the
tumours were excised, washed, fixed in
10% buffered formalin, embedded, sec-
tioned and mounted on microscope slides
for ARG, by procedures described above
for spheroids.
Fig. 3 shows an ARG (exposed for 17
days) of a small EMT-6 tumour (, 1.5 x
0 5 mm) which has grown from an inocu-
lum of 3000 tumour cells. Its form was an
s.c. ellipsoid with healthy tumour cells at
the periphery and a large necrotic central
region. There is an abundance of grains
over tumour cells in an intermediate rim
which begins 8-20 cells deep in the
tumour and has a width of 10-15 cells.
There is no evidence oflarge blood vessels
in this tumour, which can presumably be
related to the s.c. site at which the initial
tumour-cell inoculum came to rest, and
the lack ofangiogenesis within the tumour
during the short (8-day) growth. Fig. 4
shows an ARG (exposed for 17 days) of a
larger EMT-6 tumour ( 5'0 x 2'0 mm)
excised from a different s.c. site. This
section shows zones of healthy tumour
cells, necrosis and zones of cells adjacent
to necrosis which have bound 14C-MISO.
A large blood vessel is visible near the
centre of the section, and the cells im-
mediately around it have not retained
labelled drug. At a distance of 10-15 cells
from the vessel an intense rim of labelled
cells is seen. Examination of several serial
sections from this tumour indicates that
the pattern of bound sensitizer moves
across the tumour as this vessel moves
from one side to the other. This specific
labelling of cells at a distance from blood
vessels and adjacent to necrosis is indica-
tive of 14C-MISO being a marker for
viable hypoxic cells in solid tumours.
Again, much additional evidence is re-
quired to confirm such a conclusion.
The preliminary results described in
this report, along with those from addi-
tional in vitro cell studies, indicate that
14C-MISO is bound selectively to metabo-
lizing hypoxic cells in both single and
multicellular systems. In vivo studies have
been extended to the Lewis lung tumour
model and the 14C-MISO labelling appears
to indicate the location of hypoxic cells in
this tumour. Additional control studies
with Chinese hamster spheroids incubated
with 14C-MISO in equilibrium with various
concentrations of 02 are in progress to
determine whether the dimensions of the
rims of peripheral unlabelled cells and
deeper zones of labelled cells vary in a
manner predictable by 02 diffusion.
On the basis of these studies we believe
that a radioactively labelled marker for
viable hypoxic cells has been identified
and should be an extremely useful tool for
the study of tumour-cell biology and cell
kinetics. It should be noted that the con-
centration of MISO required to obtain
this differential labelling of hypoxic cells
would not be expected to produce radio-
sensitization or cytotoxicity. Further-
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more, preliminary experiments indicate
that the drug which remains bound to cells
subsequently cultured in vitro does not
interfere with their subsequent prolifera-
tive capacity, and is relatively stable for
at least 3 cell divisions. Using this infor-
mation we are currently attempting to
demonstrate whether or not tumour re-
growth after treatment with radiation and
cytotoxic drugs is from such labelled cells.
Whilst the applications for a hypoxic cell
marker in animal-tumour biology are
numerous, the exciting prospect for its
application in the clinic (Chapman, 1979;
Chapman et al., 1979) is now more
feasible. By labelling an appropriate
hypoxic cell sensitizer (ideally with a
serum half-life in man < 5 h) with an
appropriate y-emitting radionuclide (e.g.
77Br, half-life 57 h) a nuclear-medicine
assay for determining the extent and
location of hypoxia within tumour treat-
ment volumes ofindividual patients might
be possible. Patients would be adminis-
tered the labelled sensitizer during work-
up, and scanned at least 2 days later to
determine the location and extent of
retained activity. Such a clinical assay
would provide information which could
have a significant impact on diagnosis and
treatment design.
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